What We Know of the Prognostic Value of Lymphopenia in SARS-CoV-2 Infection

Pourbagheri-Sigaroodi, Atieh; Bashash, Davood; Olfatifar, Meysam; Salari, Sina; Abolghasemi, Hassan

Volume 12, Issue 3 ( September 2020 2020) Iranian Journal of Blood and Cancer 2020, 12(3): 75-79 | Back to browse issues page

Mendeley

Zotero

RefWorks

Pourbagheri-Sigaroodi A, Bashash D, Olfatifar M, Salari S, Abolghasemi H. What We Know of the Prognostic Value of Lymphopenia in SARS-CoV-2 Infection. Iranian Journal of Blood and Cancer 2020; 12 (3) :75-79
URL: http://ijbc.ir/article-1-1030-en.html

What We Know of the Prognostic Value of Lymphopenia in SARS-CoV-2 Infection

Atieh Pourbagheri-Sigaroodi¹

, Davood Bashash ^*²

, Meysam Olfatifar³

, Sina Salari⁴

, Hassan Abolghasemi⁵

1- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran , David_5980@yahoo.com
3- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Medical Oncology, Hematology and Bone Marrow Transplantation, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Pediatric Congenital Hematologic Disorders Research Center, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract: (3340 Views)

Background: Although by comparing the number of deaths to the total number of cases one may conclude that most of the infected cases are recovering, taking a look at the increasing statistics of deaths shows that SARS-CoV-2 continues to take its toll. Since lymphocytes are the main immune cells battling with rapidly evolving viruses, it comes as no surprise to assume that a decreased number of these propitious soldiers may contribute to poor prognosis of the wide range of viral infections, including COVID-19.
Methods: To provide a better prospect representing the prognostic value of lymphopenia in COVID-19, we searched the national library of medicine Medline/PubMed and performed a meta-analysis of pertinent literature representing information on the lymphocyte count in COVID-19 patients.
Results: The results of our meta-analysis revealed that the number of lymphocytes retains a specific clinical and biological significance in this infection and lymphopenia is seemingly an important hematological abnormality that contributes to mirror the evolution toward an unfavorable outcome.
Conclusion: The rapidly evolving nature of COVID-19 together with relentless disclosure of novel findings denotes a major limitation to the current study, and further investigations in the field of prognostic biomarkers will definitively pave the way to better manage patients with severe COVID-19.

Keywords: SARS-CoV-2, COVID-19, Prognosis, Lymphocyte, Lymphopenia, Meta-analysis

Full-Text [PDF 1265 kb] (2140 Downloads)

: Review Article | Subject: Infectious Diseases
Received: 2020/07/1 | Accepted: 2020/10/18 | Published: 2020/10/6

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb